What is Tandem Diabetes Care Inc (TNDM) stock price today?

Tandem Diabetes Care Inc (TNDM) currently trades at $18.16 per share. The stock has a market capitalization of $1.24B and a P/E ratio of —x.

Is TNDM stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Tandem Diabetes Care Inc has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -0.92.

What is Tandem Diabetes Care Inc's revenue and earnings?

Tandem Diabetes Care Inc has trailing twelve-month (TTM) revenue of $1.01B with profit margins of -20.20%. Earnings per share (EPS) is $-3.04.

Is Tandem Diabetes Care Inc financially healthy?

Tandem Diabetes Care Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -0.92 places it in the distress.

TNDM

Tandem Diabetes Care Inc

NASDAQ: TNDM · HEALTHCARE · MEDICAL DEVICES

$18.16

-2.52% today

Updated 2026-04-29

Market cap

$1.24B

P/E ratio

—

P/S ratio

1.23x

EPS (TTM)

$-3.04

Dividend yield

—

52W range

$10 – $30

Volume

2.3M

Market cap

$1.24B

P/E ratio

—

P/S ratio

1.23x

EPS (TTM)

$-3.04

Dividend yield

—

52W range

$10 – $30

Volume

2.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.0

Growth

4.0

Quality

2.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-0.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$31.19

+71.75%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy9 Buy11 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $3.10M — positive

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -0.92 — distress zone

- Thin margins at -20.20%

- Debt/equity 3.64x — high leverage

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$801.22M	$747.72M	$940.20M	$1.01B	$1.01B
Net income	$-94.59M	$-222.61M	$-96.03M	$-204.71M	$-589000.00
EPS	—	—	—	—	$-3.04
Free cash flow	$16.37M	$-58.61M	$4.99M	$-29.67M	$3.10M
Profit margin	-11.81%	-29.77%	-10.21%	-20.17%	-20.20%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TNDM	$1.24B	27	4.0	2.5	5.0	4.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Tandem Diabetes Care Inc trades at $18.16. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -0.92, it sits in the distress. TTM revenue stands at $1.01B. with profit margins at -20.20%.

Frequently asked questions

What is Tandem Diabetes Care Inc's stock price?

Tandem Diabetes Care Inc (TNDM) trades at $18.16.

Is Tandem Diabetes Care Inc overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Tandem Diabetes Care Inc (TNDM)?

The analyst target price is $31.19, representing +71.8% upside from the current price of $18.16.

What is Tandem Diabetes Care Inc's revenue?

TTM revenue is $1.01B.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-0.92 — distress.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.tandemdiabetes.com

Quick metrics

P/S ratio1.23x

ROE-97.90%

Beta1.74

50D MA$21.78

200D MA$17.97

Shares out0.07B

Float0.06B

Short ratio—

Avg volume2.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

TNDM vs LLY →TNDM vs JNJ →TNDM vs ABBV →Stock screener →